Japan's regulatory authorities have granted the latest batch approval to a group of generics that includes versions of Novartis's blockbuster antihypertensive Diovan (valsartan), which is now set to be opened up to its first such competition around the middle of the year.
Following the move by the ministry of health, labour and welfare, the Swiss firm's angiotensin II antagonist will face preparations...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?